London and US-based start-up Lindus Health has completed a $18 million Series A round of funding to scale up its mission of running innovative and faster clinical trials for various conditions. Lindus Health utilizes its technology platform and machine learning to execute clinical trials from start to finish, helping treatments reach patients more quickly. The funding comes from lead investor Creandum, along with participation from PayPal co-founder Peter Thiel and other returning investors. The company has already delivered over 80 clinical trials across the US, UK, and Europe and is now launching trials for treatments targeting menopause, tinnitus, insomnia, and childhood myopia. With the funding, Lindus Health plans to expand its technology platform and deliver more end-to-end clinical trials.
Lindus Health, launched in 2021 by Michael Young and Meri Beckwith, has collaborated with 20,000 patients to find new treatments for chronic conditions.
The company has a team of 40 individuals from companies such as Meta, Google, Oxford University, and Optum Health. Lindus Health is currently hiring for various roles and aims to revolutionize the clinical trials industry by creating a more agile and productive life sciences sector.
Commenting on the funding round, Michael Young, Co-Founder of Lindus Health, emphasized the significant role that clinical trials play in improving human health and stated that the company delivers trials three times faster than the industry standard. Meri Beckwith, Co-Founder of Lindus Health, expressed excitement about accelerating the pace and scale of their work with high-growth companies to bring breakthrough treatments to patients. Fredrik Cassel, General Partner at Creandum, commended Lindus Health's tech-first approach to disrupting the clinical trials industry and highlighted the potential of Lindus Health in improving global health.
Click here for a full list of 6,481+ startup investors in the UK